Colitis-ulcerosa-assoziierte Karzinogenese

André T, Shiu K‑K, Kim TW et al (2020) Pembrolizumab in microsatellite-instability–high advanced colorectal cancer. N Engl J Med 383:2207–2218 Aust DE, Baretton GB, Waldman FM et al (1999) Molecular carcinogenesis in ulcerative colitis-associated and sporadic colorectal carcinoma--differences and similarities. Verh Dtsch Ges Pathol 83:130–138 Aust DE, Terdiman JP, Willenbucher RF et al (2002) The APC/beta-catenin pathway in ulcerative colitis-related colorectal carcinomas: a mutational analysis. Cancer 94:1421–1427 Authors and Collaborators (2019) Updated S3-guideline ulcerative colitis. German society for digestive and metabolic diseases (DGVS). Z Gastroenterol 57:162–241 Bajpai M, Seril DN, Van Gurp J et al (2019) Effect of long-term mesalamine therapy on cancer-associated gene expression in colonic mucosa of patients with ulcerative colitis. Dig Dis Sci 64:740–750 Beaugerie L, Itzkowitz SH (2015) Cancers complicating inflammatory bowel disease. N Engl J Med 372:1441–1452 Biarc J, Nguyen IS, Pini A et al (2004) Carcinogenic properties of proteins with pro-inflammatory activity from streptococcus infantarius (formerly S.bovis). Carcinogenesis 25:1477–1484 Carrat F, Seksik P, Colombel JF et al (2017) The effects of aminosalicylates or thiopurines on the risk of colorectal cancer in inflammatory bowel disease. Aliment Pharmacol Ther 45:533–541 Chen DS, Irving BA, Hodi FS (2012) Molecular pathways: next-generation immunotherapy--inhibiting programmed death-ligand 1 and programmed death‑1. Clin Cancer Res 18:6580–6587 Chen DS, Mellman I (2013) Oncology meets immunology: the cancer-immunity cycle. Immunity 39:1–10 Fan X, Jin Y, Chen G et al (2021) Gut microbiota dysbiosis drives the development of colorectal cancer. Digestion 102:508–515 Fleisher AS, Esteller M, Harpaz N et al (2000) Microsatellite instability in inflammatory bowel disease-associated neoplastic lesions is associated with hypermethylation and diminished expression of the DNA mismatch repair gene, hMLH1. Cancer Res 60:4864–4868 Gao J, Shi LZ, Zhao H et al (2016) Loss of IFN‑γ pathway genes in tumor cells as a mechanism of resistance to anti-CTLA‑4 therapy. Cell 167:397–404.e9 Gordillo J, Cabre E, Garcia-Planella E et al (2015) Thiopurine therapy reduces the incidence of colorectal neoplasia in patients with ulcerative colitis. Data from the ENEIDA registry. J Crohns Colitis 9:1063–1070 Hartnett L, Egan LJ (2012) Inflammation, DNA methylation and colitis-associated cancer. Carcinogenesis 33:723–731 Li W, Zhao T, Wu D et al (2022) Colorectal cancer in ulcerative colitis: mechanisms, surveillance and chemoprevention. Curr Oncol 29:6091–6114 Lizardo DY, Kuang C, Hao S et al (2020) Immunotherapy efficacy on mismatch repair-deficient colorectal cancer: from bench to bedside. Biochim Biophys Acta Rev Cancer 1874:188447 Lu Y, Li X, Liu S et al (2018) Toll-like receptors and inflammatory bowel disease. Front Immunol 9:72 Lucafo M, Curci D, Franzin M et al (2021) Inflammatory bowel disease and risk of colorectal cancer: an overview from pathophysiology to pharmacological prevention. Front Pharmacol 12:772101 Ozawa N, Yokobori T, Osone K et al (2021) PD-L1 upregulation is associated with activation of the DNA double-strand break repair pathway in patients with colitic cancer. Sci Rep 11(1):13077. https://doi.org/10.1038/s41598-021-92530-3 Parada Venegas D, De la Fuente MK, Landskron G et al (2019) Short chain fatty acids (SCFas)-mediated gut epithelial and immune regulation and its relevance for inflammatory bowel diseases. Front Immunol 10:277 Pasternak B, Svanstrom H, Schmiegelow K et al (2013) Use of azathioprine and the risk of cancer in inflammatory bowel disease. Am J Epidemiol 177:1296–1305 Potter JD (1999) Colorectal cancer: molecules and populations. J Natl Cancer Inst 91:916–932 Qiu X, Ma J, Wang K et al (2017) Chemopreventive effects of 5‑aminosalicylic acid on inflammatory bowel disease-associated colorectal cancer and dysplasia: a systematic review with meta-analysis. Oncotarget 8:1031–1045 Quandt J, Arnovitz S, Haghi L et al (2021) Wnt-beta-catenin activation epigenetically reprograms T(reg) cells in inflammatory bowel disease and dysplastic progression. Nat Immunol 22:471–484 Raine T, Bonovas S, Burisch J et al (2022) ECCO guidelines on therapeutics in ulcerative colitis: medical treatment. J Crohns Colitis 16:2–17 Rajamaki K, Taira A, Katainen R et al (2021) Genetic and epigenetic characteristics of inflammatory bowel disease-associated colorectal cancer. Gastroenterology 161:592–607 Richard ML, Liguori G, Lamas B et al (2018) Mucosa-associated microbiota dysbiosis in colitis associated cancer. Gut Microbes 9:131–142 Sheng YH, Giri R, Davies J et al (2021) A nucleotide analog prevents colitis-associated cancer via beta-catenin independently of inflammation and autophagy. Cell Mol Gastroenterol Hepatol 11:33–53 Sorbara MT, Dubin K, Littmann ER et al (2019) Inhibiting antibiotic-resistant enterobacteriaceae by microbiota-mediated intracellular acidification. J Exp Med 216:84–98 Terdiman JP, Steinbuch M, Blumentals WA et al (2007) 5‑Aminosalicylic acid therapy and the risk of colorectal cancer among patients with inflammatory bowel disease. Inflamm Bowel Dis 13:367–371 Topalian SL, Drake CG, Pardoll DM (2015) Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell 27:450–461 Wijnands AM, de Jong ME, Lutgens MWMD et al (2021) Prognostic factors for advanced colorectal neoplasia in inflammatory bowel disease: systematic review and meta-analysis. Gastroenterology 160:1584–1598 Willenbucher RF, Aust DE, Chang CG et al (1999) Genomic instability is an early event during the progression pathway of ulcerative-colitis-related neoplasia. Am J Pathol 154:1825–1830 Yang Y, Gharaibeh RZ, Newsome RC et al (2020) Amending microbiota by targeting intestinal inflammation with TNF blockade attenuates development of colorectal cancer. Nat Cancer 1:723–734 Zhang Y, Weng Y, Gan H et al (2018) Streptococcus gallolyticus conspires myeloid cells to promote tumorigenesis of inflammatory bowel disease. Biochem Biophys Res Commun 506:907–911